Amarin Corporation plc (AMRN)
| Market Cap | 203.37M |
| Revenue (ttm) | 241.02M |
| Net Income (ttm) | -39.35M |
| Shares Out | 411.34M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,565,382 |
| Open | 0.500 |
| Previous Close | 0.491 |
| Day's Range | 0.477 - 0.500 |
| 52-Week Range | 0.460 - 1.370 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboratio... [Read more]
Financial Performance
In 2023, Amarin Corporation's revenue was $306.91 million, a decrease of -16.87% compared to the previous year's $369.19 million. Losses were -$59.11 million, -44.13% less than in 2022.
Financial StatementsNews
Top 3 Health Care Stocks You'll Regret Missing In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations ...
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCE...
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® car...
Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Aaron...
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation – -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKE...
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CV...
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members o...
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG)...
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin...
Amarin Board of Directors Announces CEO Transition
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1....
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is sche...
Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Patrick...
Amarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4...
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlig...
Amarin Announces Results of Annual General Meeting of Shareholders
- Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, a...
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American Col...
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOB...
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 -- -- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash ...
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, an...